-Reuters
Wells Fargo Maintains Overweight on Karuna Therapeutics, Raises Price Target to $264
Wells Fargo analyst Jacob Hughes maintains Karuna Therapeutics (NASDAQ:KRTX) with a Overweight and raises the price target from $186 to $264.
Related Posts
Taboola.com Q4 Adj EPS $0.16 Beats $0.16 Estimate, Sales $371.27M Beat $367.49M Estimate
Taboola.com (NASDAQ:TBLA) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.16 by 2.5 percent. The company reported quarterly sales of $371.27 million which beat the analyst
InterDigital Registers 23% Revenue Growth In Q1 Reflecting Licensing Momentum, Recurring Revenue Base
InterDigital, Inc (NASDAQ:IDCC) reported first-quarter FY22 revenue growth of 23% year-on-year to $101.3 million, beating the consensus of $97.9 million. Recurring…